Protein Replacement Therapies for Rare Diseases: A Breeze for Regulatory Approval?

    loading  Checking for direct PDF access through Ovid

Abstract

Protein replacement therapies for rare monogenic diseases have a higher probability of regulatory approval compared with biologics, small molecules, and grant-funded orphan drugs.

Related Topics

    loading  Loading Related Articles